Soleus Capital Management’s Castle Biosciences CSTL Stock Holding History

Soleus Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-252,917	Closed	-$6.74M	–	80
2024 Q4	$6.74M	Sell	252,917 -409,415	-62%	-$12.5M	0.42%	50
2024 Q3	$18.9M	Sell	662,332 -191,296	-22%	-$4.87M	1.46%	22
2024 Q2	$18.6M	Buy	853,628 +128,171	+18%	+$2.86M	1.64%	22
2024 Q1	$16.1M	Buy	725,457 +699,457	+2,690%	+$15.2M	1.19%	25
2023 Q4	$561K	Sell	26,000 -257,500	-91%	-$4.53M	0.06%	66
2023 Q3	$4.79M	Buy	+283,500	New	+$4.96M	0.44%	57
2022 Q4	–	Sell	-297,840	Closed	-$7.77M	–	77
2022 Q3	$7.77M	Buy	+297,840	New	+$8.35M	1.06%	29
2020 Q4	–	Sell	-6,269	Closed	-$323K	–	69
2020 Q3	$323K	Sell	6,269 -8,731	-58%	-$388K	0.17%	58
2020 Q2	$565K	Buy	+15,000	New	+$513K	0.32%	54

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Soleus Capital Management's CSTL Position: Q1 2025 in Review

Soleus Capital Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 252,917 shares — an estimated $6.74M sold.

Soleus Capital Management first reported a position in CSTL in Q2 2020 and held it in 9 quarters. The position peaked at $18.9M in Q3 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

Soleus Capital Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
Soleus Capital Management sold 252,917 Castle Biosciences shares in Q1 2025, an estimated $6.74M.
Soleus Capital Management first reported a position in Castle Biosciences in Q2 2020 and held it in 9 quarters.
Soleus Capital Management's Castle Biosciences position peaked at $18.9M in Q3 2024.
180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.